慢性乙型肝炎患者ETV/TDF应答不佳研究进展  

Progress on suboptimal response to ETV/TDF of chronic hepatitis B

作　　者：李海福 黄泽炳[1] 黄燕[1] Li Haifu;Huang Zebing;Huang Yan(Department of Infectious Diseases,Xiangya Hospital,Central South University,Changsha 410008,China)

机构地区：[1]中南大学湘雅医院感染病科,长沙410008

出　　处：《中国肝脏病杂志（电子版）》2023年第1期34-39,共6页Chinese Journal of Liver Diseases：Electronic Version

基　　金：国家自然科学基金(81970550);湖南省自然科学基金(2021JJ31067)。

摘　　要：乙型肝炎病毒(hepatitis B virus,HBV)感染严重危害人类健康,一线核苷(酸)类似物[nucleos(t)ide analogues,NAs]抗病毒治疗是目前临床广泛使用的有效治疗措施之一,但恩替卡韦(entecavir,ETV)/替诺福韦酯(tenofovir disoproxil fumarate,TDF)应答不佳降低了抗病毒治疗有效率。目前应答不佳评估标准尚未形成统一共识,亦缺乏明确的流行病学资料,对于应答不佳的原因、危害有待进一步研究,治疗策略仍有待验证。本文主要就ETV/TDF应答不佳的评估标准、原因、危害及NAs治疗方案进行综述。Hepatitis B virus(HBV)infection is severely threatening human health.Antiviral therapy with first-line nucleos(t)ide analogues(NAs)is one of the effective treatments,but suboptimal responses to entecavir(ETV)and tenofovir disoproxil fumarate(TDF)reduce the effective rate of antiviral therapy.There is no consensus on evaluation criteria for suboptimal response,and epidemiological data is scarce at present.The causes and harms of suboptimal response need to be furtherly investigated and treatment strategies still need to be verified.This review aimed to introduce the evaluation criteria,causes,harms and therapeutic regimen of NAs for suboptimal response to ETV and TDF.

关 键 词：肝炎病毒 乙型 恩替卡韦 替诺福韦酯 应答不佳 

分 类 号：R512.62[医药卫生—内科学]